PTSD

Transformational synergies: Experiential-relational psychotherapeutic interventions can accelerate the healing of attachment trauma

MDMA optimizes brain chemistry for safety, openness, and compassion. AEDP uses relational interventions to enhance MDMA's effects in trauma therapy, fostering trust, intimacy, and healing attachment.

Kari Gleiser

PS2023 Cannabis Health Conditions Psychedelic Assisted Therapy PTSD Research and Science Veterans

Phase 2 Multicenter Randomized Placebo-controlled, Double-blind Study to Assess Safety/Efficacy of Inhaled Cannabis in Veterans for PTSD

Study aims to re-examine inhaled cannabis for treating PTSD, with Phase 2 study assessing high THC cannabis versus placebo for managing symptoms and pain in 360 veterans across U.S.

Sue Sisley, Shane Pennington

PS2023 Depression Health Equity Policy and Advocacy Psychedelic Assisted Therapy PTSD Veterans

Healing Our Heroes: A Dinner Honoring Veterans and First Responders

Veterans, First Responders, and families supporting psychedelic medicine will be honored at the conference for their mental health challenges and the urgent need for better care and resources.

Itzel Barakat, Justin LaPree

PS2023 MDMA MDMA-AT Policy and Advocacy Psychedelic Science PTSD Research

The Light of Psychedelics in a Dark World

Rick Doblin reflects on 38 years of MAPS, discussing psychedelic milestones and obstacles. Lykos Therapeutics submits NDA for MDMA-assisted therapy for PTSD in December 2023.

Rick Doblin

PS2023 Health Conditions MDMA Psychedelic Assisted Therapy PTSD Research and Science Therapy Ethics

Trauma and psychedelic-assisted therapy

Dr. Barbara Rothbaum discusses combining MDMA with prolonged exposure therapy for PTSD, citing theoretical and translational research supporting a synergistic mechanism of action for treatment.

Barbara Rothbaum, Lynnette A. Averill

PS2023 Healing for All Integration Psychedelic Assisted Therapy Psychedelic Science PTSD Research

Mind-Body Skills Groups as a Potential Ideal Setting for Psychedelic Exploration

James S. Gordon, MD, psychiatrist and author, shares how Mind-Body Skills Groups have reduced PTSD diagnoses by 80%, discussing their techniques and the potential integration of psychedelic experiences.

James Gordon

PS2023 MDMA Psychedelic Assisted Therapy PTSD Research and Science Therapy Ethics

Couples therapy and psychedelic-assisted therapy

Dr. Anne Wagner and Dr. Michael Mithoefer discuss therapeutic potential of MDMA for couples, sharing insights from their MDMA-assisted couples therapy trials and ongoing research with Dr. Chandra Khalifian and

Chandra Khalifian, Leslie Morland, Kayla Knopp

PS2023 MDMA MDMA-AT Policy and Advocacy Psychedelic Assisted Therapy PTSD Research

Pioneers of MDMA Therapy: Reflections on 20+ Years of MDMA Therapy and Research

MAPS completes Phase 3 study for MDMA-AT in PTSD treatment, marking historic milestone in psychedelic drug research. Safety and efficacy of MDMA-assisted therapy still under investigation.

Keren Tzarfaty, Michael Mithoefer, Julie Holland

PS2023 Health Conditions MDMA MDMA-AT Psychedelic Assisted Therapy PTSD Research and Science

Investigational MDMA-assisted therapy and eating disorder symptoms in a randomized placebo-controlled trial for severe PTSD

MDMA-assisted therapy (MDMA-AT) shows promise in treating PTSD and comorbid eating disorders. A study found significant reductions in eating disorder symptoms with MDMA-AT compared to placebo in severe PTSD patients.

Adele LaFrance, Timothy Brewerton

PS2023 Anxiety Depression Ibogaine PTSD Research Veterans

Ibogaine-Magnesium: the Stanford Traumatic Injury to the CNS (MISTIC) Protocol – A Pilot Study in Special Operations Veterans with Traumatic Brain Injuries

Stanford conducted the first trial of Magnesium-Ibogaine on Special Operations Forces Veterans with traumatic brain injury, showing significant functional improvements and high remission rates for comorbid psychiatric disorders. Further controlled

Nolan Williams